Newsroom

08

November 2017

Wednesday

iX Biopharma Ltd. has reported results for the first financial quarter ended 30 September 2017 (unaudited).

Meanwhile, the Group is finalising its marketing campaign for a new line of nutraceutical supplements addressing specific health conditions, under its subsidiary Entity Health. 

More information can be found in the attached press release. The first quarter financial statements for the period can be found here.

24

October 2017

Tuesday

iX Biopharma Ltd. delivered a product presentation immediately following the conclusion of the AGM and EGM held on 24 October 2017. The presentation slides can be accessed using the links below:

English version

Chinese version

24

October 2017

Tuesday

iX Biopharma Ltd. is pleased to announce the results of its Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) held on 24 October 2017. They can be viewed at the links below:

AGM Results

EGM Results

24

October 2017

Tuesday

iX Biopharma Ltd. is pleased to announce that it has been granted a European patent for its WaferiX™ drug delivery technology.

More information can be found in the attached press release.

28

September 2017

Thursday

The Annual General Meeting of iX Biopharma Ltd. (the “Company”) will be held at NUSS Kent Ridge Guild House, Inner Chamber, 9 Kent Ridge Drive, Singapore 119241 on Tuesday, 24 October 2017, at 10.00 a.m.. An Extraordinary General Meeting of the Company will be held at 11.30 a.m. (or as soon as practicable immediately following the conclusion or adjournment of the Annual General Meeting of the Company) on the same day and at the same place for the purpose of considering the proposed adoption of a new constitution of the Company.

The Notice of Annual General Meeting can be found here. The Circular to Shareholders in relation to the proposed adoption of the new constitution of the Company and the Notice of Extraordinary General Meeting can be found here.

28

September 2017

Thursday

iX Biopharma Ltd. is pleased to annouce that the Annual Report 2017 has been released. 

The Annual Report 2017 can be found here.

23

August 2017

Wednesday

iX Biopharma Ltd. has reported results for the fourth financial quarter ended 30 June 2017 (unaudited).

Meanwhile, the Group commenced a multi-dose Phase 2 efficacy study with Wafermine (KET010) in the USA.

More information can be found in the attached press releaseThe fourth quarter financial statements for the period can be found here.

15

May 2017

Monday

iX Biopharma Ltd. has incorporated a new wholly owned subsidiary, Entity Health Pte Ltd (“Entity”), to promote and market its new line of products: supplements addressing specific conditions. Entity will be the Group’s third business arm, complementing its existing pharmaceutical business and chemical analysis business.

More information can be found in the attached press release.

15

May 2017

Monday

Homegrown specialty pharmaceutical company iX Biopharma Ltd. is pleased to announce the results of BUP001, a pharmacokinetic study of its novel sublingual buprenorphine wafer, BnoX.

More information can be found in the attached press release.

11

May 2017

Thursday

iX Biopharma Ltd. has reported results for the third financial quarter ended 31 March 2017 (unaudited).

Meanwhile, the Group is currently making preparations to launch WafeRest™ in Singapore and the region in the second half of 2017. 

More information can be found in the attached press release. The third quarter financial statements for the period can be found here.

For all company announcements, please refer to SGX company disclosures page.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com